二线治疗-话题@MedSci

#二线治疗#

120篇内容 | 1950人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1543964, encodeId=4a761543964d3, content=<a href='/topic/show?id=02982402298' target=_blank style='color:#2F92EE;'>#二线治疗#</a>, objectTitle=NEJM：HIV感染二线治疗选择——度鲁特韦方案vs达芦那韦方案, objectType=article, longId=214784, objectId=2ebb214e8446, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2ebb214e8446, replyNumber=0, likeNumber=46, createdTime=2021-07-27, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2ebb214e8446, moduleTitle=NEJM：HIV感染二线治疗选择——度鲁特韦方案vs达芦那韦方案, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2ebb214e8446)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1543963, encodeId=41a0154396310, content=<a href='/topic/show?id=02982402298' target=_blank style='color:#2F92EE;'>#二线治疗#</a>, objectTitle=NEJM：鲁索利替尼二线治疗慢性移植物抗宿主病效果显著, objectType=article, longId=214303, objectId=767321430300, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=767321430300, replyNumber=0, likeNumber=41, createdTime=2021-07-17, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=767321430300, moduleTitle=NEJM：鲁索利替尼二线治疗慢性移植物抗宿主病效果显著, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=767321430300)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1543962, encodeId=b0f91543962c9, content=<a href='/topic/show?id=02982402298' target=_blank style='color:#2F92EE;'>#二线治疗#</a>, objectTitle=J Clin Oncol: 帕博利珠单抗+GVD（吉西他滨、长春瑞宾和脂质体阿霉素）二线治疗复发或难治性经典霍奇金淋巴瘤的疗效和安全性, objectType=article, longId=213317, objectId=1fc021331e00, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1fc021331e00, replyNumber=0, likeNumber=53, createdTime=2021-06-28, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1fc021331e00, moduleTitle=J Clin Oncol: 帕博利珠单抗+GVD（吉西他滨、长春瑞宾和脂质体阿霉素）二线治疗复发或难治性经典霍奇金淋巴瘤的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1fc021331e00)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1543961, encodeId=fc0d1543961b6, content=<a href='/topic/show?id=02982402298' target=_blank style='color:#2F92EE;'>#二线治疗#</a>, objectTitle=Ann Oncol: 纳武利尤单抗（Nivolumab）二线治疗并不能改善小细胞肺癌的预后：来自CheckMate 331临床研究, objectType=article, longId=212154, objectId=c931212154fa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c931212154fa, replyNumber=0, likeNumber=38, createdTime=2021-06-03, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c931212154fa, moduleTitle=Ann Oncol: 纳武利尤单抗（Nivolumab）二线治疗并不能改善小细胞肺癌的预后：来自CheckMate 331临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c931212154fa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1543960, encodeId=86a51543960fd, content=<a href='/topic/show?id=02982402298' target=_blank style='color:#2F92EE;'>#二线治疗#</a>, objectTitle=Lancet Oncol：积极症状控制联合FOLFOX化疗可有效延长二线治疗晚期胆道癌患者生存期, objectType=article, longId=209579, objectId=b43d2095e9ba, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b43d2095e9ba, replyNumber=0, likeNumber=53, createdTime=2021-04-06, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b43d2095e9ba, moduleTitle=Lancet Oncol：积极症状控制联合FOLFOX化疗可有效延长二线治疗晚期胆道癌患者生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b43d2095e9ba)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1543959, encodeId=aeab154395983, content=<a href='/topic/show?id=02982402298' target=_blank style='color:#2F92EE;'>#二线治疗#</a>, objectTitle=J Thorac Oncol：RovalPituzumab tesiine与拓扑替康用作小细胞肺癌二线治疗方案的疗效对比, objectType=article, longId=207881, objectId=1b2f20e88186, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1b2f20e88186, replyNumber=0, likeNumber=46, createdTime=2021-03-06, rootId=0, userName=ms5768352621950538, userId=520213623738, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1b2f20e88186, moduleTitle=J Thorac Oncol：RovalPituzumab tesiine与拓扑替康用作小细胞肺癌二线治疗方案的疗效对比, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1b2f20e88186)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1543958, encodeId=e43f154395834, content=<a href='/topic/show?id=02982402298' target=_blank style='color:#2F92EE;'>#二线治疗#</a>, objectTitle=JCO：Pegilodecakin+FOLFOX二线治疗未能改善吉西他滨难治性转移性胰腺癌的疗效, objectType=article, longId=207010, objectId=0c9920e0107e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0c9920e0107e, replyNumber=0, likeNumber=40, createdTime=2021-02-11, rootId=0, userName=ms5768352621950538, userId=520213623738, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0c9920e0107e, moduleTitle=JCO：Pegilodecakin+FOLFOX二线治疗未能改善吉西他滨难治性转移性胰腺癌的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0c9920e0107e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1543957, encodeId=70f8154395ee8, content=<a href='/topic/show?id=02982402298' target=_blank style='color:#2F92EE;'>#二线治疗#</a>, objectTitle=一项在真实世界中的研究：格列齐特缓释片和西格列汀作为二甲双胍单药治疗控制不佳的2型糖尿病患者二线治疗的疗效比较, objectType=article, longId=205833, objectId=25a8205833ad, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=25a8205833ad, replyNumber=0, likeNumber=20, createdTime=2021-01-20, rootId=0, userName=ms5768352621950538, userId=520213623738, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=25a8205833ad, moduleTitle=一项在真实世界中的研究：格列齐特缓释片和西格列汀作为二甲双胍单药治疗控制不佳的2型糖尿病患者二线治疗的疗效比较, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=25a8205833ad)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1543956, encodeId=401e154395654, content=<a href='/topic/show?id=02982402298' target=_blank style='color:#2F92EE;'>#二线治疗#</a>, objectTitle=Zepzelca在美国获批，二线治疗转移性小细胞肺癌, objectType=article, longId=195956, objectId=6c89195956f1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6c89195956f1, replyNumber=0, likeNumber=35, createdTime=2020-06-18, rootId=0, userName=ms5768352621950538, userId=520213623738, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6c89195956f1, moduleTitle=Zepzelca在美国获批，二线治疗转移性小细胞肺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6c89195956f1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1543955, encodeId=3524154395561, content=<a href='/topic/show?id=02982402298' target=_blank style='color:#2F92EE;'>#二线治疗#</a>, objectTitle=FDA：批准纳武利尤单抗获批食管鳞癌二线治疗, objectType=article, longId=195812, objectId=6d62195812c1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6d62195812c1, replyNumber=0, likeNumber=0, createdTime=2020-06-14, rootId=0, userName=ms5768352621950538, userId=520213623738, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6d62195812c1, moduleTitle=FDA：批准纳武利尤单抗获批食管鳞癌二线治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6d62195812c1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1543954, encodeId=5da9154395425, content=<a href='/topic/show?id=02982402298' target=_blank style='color:#2F92EE;'>#二线治疗#</a>, objectTitle=Lancet Oncol：卡瑞利珠单抗二线治疗食管癌 III 期研究结果公布，患者死亡风险减少三成（ESCORT试验）, objectType=article, longId=194143, objectId=2d2a194143a2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2d2a194143a2, replyNumber=0, likeNumber=20, createdTime=2020-05-15, rootId=0, userName=仁医06, userId=55683, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2d2a194143a2, moduleTitle=Lancet Oncol：卡瑞利珠单抗二线治疗食管癌 III 期研究结果公布，患者死亡风险减少三成（ESCORT试验）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2d2a194143a2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1543953, encodeId=174015439536c, content=<a href='/topic/show?id=02982402298' target=_blank style='color:#2F92EE;'>#二线治疗#</a>, objectTitle=Lancet Oncol：Lurbinectedin二线治疗小细胞肺癌, objectType=article, longId=191118, objectId=83c5191118cc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=83c5191118cc, replyNumber=0, likeNumber=35, createdTime=2020-04-01, rootId=0, userName=ms5768352621950538, userId=520213623738, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=83c5191118cc, moduleTitle=Lancet Oncol：Lurbinectedin二线治疗小细胞肺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=83c5191118cc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1543952, encodeId=eb83154395290, content=<a href='/topic/show?id=02982402298' target=_blank style='color:#2F92EE;'>#二线治疗#</a>, objectTitle=豪森药业第三代EGFR TKI在中国获批用于EGFR T790M突变型非小细胞肺癌的二线治疗, objectType=article, longId=190514, objectId=8e2119051451, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8e2119051451, replyNumber=0, likeNumber=33, createdTime=2020-03-22, rootId=0, userName=ms5768352621950538, userId=520213623738, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8e2119051451, moduleTitle=豪森药业第三代EGFR TKI在中国获批用于EGFR T790M突变型非小细胞肺癌的二线治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8e2119051451)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1543951, encodeId=583d1543951a1, content=<a href='/topic/show?id=02982402298' target=_blank style='color:#2F92EE;'>#二线治疗#</a>, objectTitle=Opdivo+Yervoy二线治疗肝细胞癌被FDA批准, objectType=article, longId=190102, objectId=724a19010294, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=724a19010294, replyNumber=0, likeNumber=26, createdTime=2020-03-18, rootId=0, userName=ms5768352621950538, userId=520213623738, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=724a19010294, moduleTitle=Opdivo+Yervoy二线治疗肝细胞癌被FDA批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=724a19010294)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1543950, encodeId=8e52154395025, content=<a href='/topic/show?id=02982402298' target=_blank style='color:#2F92EE;'>#二线治疗#</a>, objectTitle=NEJM：曲妥珠单抗-美坦新偶联物二线治疗HER-2转移性乳腺癌, objectType=article, longId=187963, objectId=d19718e96350, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d19718e96350, replyNumber=0, likeNumber=32, createdTime=2020-02-15, rootId=0, userName=ms5768352621950538, userId=520213623738, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d19718e96350, moduleTitle=NEJM：曲妥珠单抗-美坦新偶联物二线治疗HER-2转移性乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d19718e96350)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1543949, encodeId=9dbc15439491e, content=<a href='/topic/show?id=02982402298' target=_blank style='color:#2F92EE;'>#二线治疗#</a>, objectTitle=Frontier in Pharmacology：HIV感染者使用LPV/r二线治疗的长期、大规模、多中心、真实世界研究结果发布, objectType=article, longId=186097, objectId=245d18609efa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=245d18609efa, replyNumber=0, likeNumber=17, createdTime=2020-01-13, rootId=0, userName=ms5768352621950538, userId=520213623738, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=245d18609efa, moduleTitle=Frontier in Pharmacology：HIV感染者使用LPV/r二线治疗的长期、大规模、多中心、真实世界研究结果发布, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=245d18609efa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1543948, encodeId=54a21543948fb, content=<a href='/topic/show?id=02982402298' target=_blank style='color:#2F92EE;'>#二线治疗#</a>, objectTitle=J Rheumatol：类风湿性关节炎b/tsDMARD停药和坚持二线治疗的原因, objectType=article, longId=184790, objectId=3498184e9022, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3498184e9022, replyNumber=0, likeNumber=49, createdTime=2019-12-17, rootId=0, userName=ms5768352621950538, userId=520213623738, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3498184e9022, moduleTitle=J Rheumatol：类风湿性关节炎b/tsDMARD停药和坚持二线治疗的原因, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3498184e9022)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1543947, encodeId=e0b3154394e37, content=<a href='/topic/show?id=02982402298' target=_blank style='color:#2F92EE;'>#二线治疗#</a>, objectTitle=NEJM：Asciminib二线治疗费城染色体阳性白血病, objectType=article, longId=184673, objectId=05d51846e3ec, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=05d51846e3ec, replyNumber=0, likeNumber=25, createdTime=2019-12-14, rootId=0, userName=ms5768352621950538, userId=520213623738, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=05d51846e3ec, moduleTitle=NEJM：Asciminib二线治疗费城染色体阳性白血病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=05d51846e3ec)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1543946, encodeId=90d915439460f, content=<a href='/topic/show?id=02982402298' target=_blank style='color:#2F92EE;'>#二线治疗#</a>, objectTitle=NEJM：曲妥珠单抗Deruxtecan用于HER2阳性转移性乳腺癌的二线治疗, objectType=article, longId=184671, objectId=d1461846e154, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d1461846e154, replyNumber=0, likeNumber=37, createdTime=2019-12-14, rootId=0, userName=ms5768352621950538, userId=520213623738, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d1461846e154, moduleTitle=NEJM：曲妥珠单抗Deruxtecan用于HER2阳性转移性乳腺癌的二线治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d1461846e154)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1543945, encodeId=c8781543945fb, content=<a href='/topic/show?id=02982402298' target=_blank style='color:#2F92EE;'>#二线治疗#</a>, objectTitle=信迪利单抗联合化疗用于晚期肺鳞癌二线治疗，肿瘤持续缓解7个月以上, objectType=article, longId=181304, objectId=4eaa18130437, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4eaa18130437, replyNumber=0, likeNumber=50, createdTime=2019-10-17, rootId=0, userName=ms5768352621950538, userId=520213623738, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4eaa18130437, moduleTitle=信迪利单抗联合化疗用于晚期肺鳞癌二线治疗，肿瘤持续缓解7个月以上, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4eaa18130437)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

二线治疗

2020-05-29

智者为医08 (审核中...)

前往app查看评论内容

#二线治疗#

NEJM：HIV感染二线治疗选择——度鲁特韦方案vs达芦那韦方案

2021-07-27

智者为医08 (审核中...)

前往app查看评论内容

#二线治疗#

NEJM：鲁索利替尼二线治疗慢性移植物抗宿主病效果显著

2021-07-17

智者为医08 (审核中...)

前往app查看评论内容

#二线治疗#

J Clin Oncol: 帕博利珠单抗+GVD（吉西他滨、长春瑞宾和脂质体阿霉素）二线治疗复发或难治性经典霍奇金淋巴瘤的疗效和安全性

2021-06-28

智者为医08 (审核中...)

前往app查看评论内容

#二线治疗#

Ann Oncol: 纳武利尤单抗（Nivolumab）二线治疗并不能改善小细胞肺癌的预后：来自CheckMate 331临床研究

2021-06-03

智者为医08 (审核中...)

前往app查看评论内容

#二线治疗#

Lancet Oncol：积极症状控制联合FOLFOX化疗可有效延长二线治疗晚期胆道癌患者生存期

2021-04-06

ms5768352621950538 (审核中...)

前往app查看评论内容

#二线治疗#

J Thorac Oncol：RovalPituzumab tesiine与拓扑替康用作小细胞肺癌二线治疗方案的疗效对比

2021-03-06

ms5768352621950538 (审核中...)

前往app查看评论内容

#二线治疗#

JCO：Pegilodecakin+FOLFOX二线治疗未能改善吉西他滨难治性转移性胰腺癌的疗效

2021-02-11

ms5768352621950538 (审核中...)

前往app查看评论内容

#二线治疗#

一项在真实世界中的研究：格列齐特缓释片和西格列汀作为二甲双胍单药治疗控制不佳的2型糖尿病患者二线治疗的疗效比较

2021-01-20

ms5768352621950538 (审核中...)

前往app查看评论内容

#二线治疗#

Zepzelca在美国获批，二线治疗转移性小细胞肺癌

2020-06-18

ms5768352621950538 (审核中...)

前往app查看评论内容

#二线治疗#

FDA：批准纳武利尤单抗获批食管鳞癌二线治疗

2020-06-14

仁医06 (审核中...)

前往app查看评论内容

#二线治疗#

Lancet Oncol：卡瑞利珠单抗二线治疗食管癌 III 期研究结果公布，患者死亡风险减少三成（ESCORT试验）

2020-05-15

ms5768352621950538 (审核中...)

前往app查看评论内容

#二线治疗#

Lancet Oncol：Lurbinectedin二线治疗小细胞肺癌

2020-04-01

ms5768352621950538 (审核中...)

前往app查看评论内容

#二线治疗#

豪森药业第三代EGFR TKI在中国获批用于EGFR T790M突变型非小细胞肺癌的二线治疗

2020-03-22

ms5768352621950538 (审核中...)

前往app查看评论内容

#二线治疗#

Opdivo+Yervoy二线治疗肝细胞癌被FDA批准

2020-03-18

ms5768352621950538 (审核中...)

前往app查看评论内容

#二线治疗#

NEJM：曲妥珠单抗-美坦新偶联物二线治疗HER-2转移性乳腺癌

2020-02-15

ms5768352621950538 (审核中...)

前往app查看评论内容

#二线治疗#

Frontier in Pharmacology：HIV感染者使用LPV/r二线治疗的长期、大规模、多中心、真实世界研究结果发布

2020-01-13

ms5768352621950538 (审核中...)

前往app查看评论内容

#二线治疗#

J Rheumatol：类风湿性关节炎b/tsDMARD停药和坚持二线治疗的原因

2019-12-17

ms5768352621950538 (审核中...)

前往app查看评论内容

#二线治疗#

NEJM：Asciminib二线治疗费城染色体阳性白血病

2019-12-14

ms5768352621950538 (审核中...)

前往app查看评论内容

#二线治疗#

NEJM：曲妥珠单抗Deruxtecan用于HER2阳性转移性乳腺癌的二线治疗

2019-12-14

ms5768352621950538 (审核中...)

前往app查看评论内容

#二线治疗#

信迪利单抗联合化疗用于晚期肺鳞癌二线治疗，肿瘤持续缓解7个月以上

2019-10-17

科室
- - 订阅+
  - 更多科室
工具
服务